Form Bio Partners with Weill Cornell Medicine to Develop Gene Editing Therapy for Alzheimer's Disease
核心洞察
Form Bio (搜索) and Weill Cornell Medicine announced a strategic collaboration to develop gene editing therapies targeting high-risk genetic variants in Alzheimer's disease (搜索) patients.
The multi-phase initiative focuses on converting the high-risk APOE4 (搜索) allele to the protective APOE3 (搜索) variant using AAV-mediated prime editing technology.
Early preclinical data demonstrates efficient gene editing of APOE4 (搜索) to APOE3 (搜索) in animal models, representing a potential breakthrough for the 7 million Americans living with Alzheimer's.
Form Bio (搜索), a leader in AI-powered genetic medicine development, has entered into a collaborative research agreement with Weill Cornell Medicine to develop gene editing therapies that could reduce Alzheimer's disease (搜索) risk in patients carrying high-risk genetic variants. The partnership, announced on October 30, 2025, represents a significant advancement in addressing one of the strongest genetic drivers of Alzheimer's disease.
Targeting the APOE4 Genetic Risk Factor
The collaboration focuses on the APOE4 (搜索) allele, a well-established genetic risk factor for Alzheimer's disease (搜索). Carriers of this variant face substantially higher likelihood of developing the condition, making it a critical target for therapeutic intervention. The research aims to convert the high-risk APOE4 allele to the protective APOE3 (搜索) variant using advanced gene editing techniques.
"Our early data has shown efficient AAV-mediated prime editing of the high risk APOE4 (搜索) allele to the low risk APOE3 (搜索) variant in a preclinical animal model of Alzheimer's disease (搜索)," said Dolan Sondhi, PhD, Principal Investigator of the project and Professor of Research in Genetic Medicine at Weill Cornell Medicine. "This research collaboration has the potential to accelerate the optimization of these vector cassettes and increase the likelihood of developing a safe and effective therapy for future clinical studies in patients with Alzheimer's disease."
Addressing a Growing Global Health Crisis
The initiative comes at a critical time as Alzheimer's disease (搜索) continues to impact millions worldwide. According to the World Health Organization data cited in the announcement, more than 7 million Americans over the age of 65 are currently living with Alzheimer's, while over 55 million people globally are affected by dementia (搜索). These numbers are projected to triple by 2050, underscoring the urgent need for effective interventions.
AI-Powered Vector Design Platform
The collaboration leverages Form Bio (搜索)'s artificial intelligence-driven vector design platform combined with Weill Cornell's expertise in neurodegenerative disease biology and gene editing. This multi-phase program aims to accelerate the path from discovery to clinical assessment through AI-powered vector design and preclinical validation.
"The combination of Weill Cornell's cutting-edge gene editing expertise and deep understanding of neurodegenerative disease biology with Form Bio (搜索)'s AI-driven vector design platform gives us a unique opportunity to explore one of the greatest unmet needs in medicine," said Michelle Chen, PhD, President and Chief Executive Officer at Form Bio. "By focusing on genetically defined high-risk patients, we're laying the groundwork for a potentially transformative approach to Alzheimer's disease (搜索)."
Strategic Partnership Structure
Form Bio (搜索), which spun out from Colossal Biosciences (搜索) in 2022, has established itself as a trusted innovation partner in cell and gene therapy development. The company's advanced computational platforms deliver insights into genome integrity and optimized payload design, enabling the development of safer and more efficacious therapeutics.
The collaboration represents the first step in what is planned as a multi-phase program, with the current focus on optimizing vector cassettes for potential future clinical studies. Dr. Dolan Sondhi serves as an advisory board member for Form Bio (搜索), Inc., providing additional strategic guidance to the partnership.